{"entity":{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","aka":[],"tldr":"OSE Immunotherapeutics develops immune treatments for cancer and inflammatory disease. Its lead cancer product is an off-the-shelf vaccine for lung cancer patients whose immunotherapy has stopped working, now in a late-stage trial.","summary":"OSE Immunotherapeutics SA (Euronext Paris: OSE), based in Nantes, is a clinical-stage company with platforms in immuno-oncology and immuno-inflammation. Tedopi (OSE2101) is an off-the-shelf neo-epitope T cell vaccine for HLA-A2 positive patients, in the phase 3 ARTEMIA trial in non-small cell lung cancer after checkpoint inhibitor failure; the trial received a second positive Independent Data Monitoring Committee recommendation in February 2026, and Tedopi showed positive phase 2 results in recurrent ovarian cancer (TEDOVA, ASCO 2026). OSE-279 is an anti-PD-1 antibody, with partnered programmes ABBV-230 (AbbVie) and BI 770371 (Boehringer Ingelheim). Outside oncology, lusvertikimab (anti-IL-7R) targets inflammatory bowel disease and pegrizeprument is partnered with Veloxis in transplantation. In May 2026 OSE signed a flexible bridge equity financing with IRIS Capital for up to about EUR 19.3 million, extending cash runway to December 2026.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ose-immuno.com"},{"label":"Press releases","url":"https://www.ose-immuno.com/en/press-releases/"},{"label":"Bridge equity financing with IRIS (May 2026)","url":"https://www.ose-immuno.com/wp-content/uploads/2026/05/OSE-PR_EN_260528_IRIS-Financing-vdef.pdf"}],"tags":[],"related":[],"cancers":["nsclc","ovarian"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine","checkpoint-inhibitor","monoclonal-antibody"],"targets":["pd1"],"drugs":["ose2101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05751798"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"Nantes","country":"FR","companyType":"biotech","website":"https://www.ose-immuno.com","ticker":"OSE.PA","stage":"public","investors":[],"funding":[{"round":"Crossover","year":2026,"source":"https://www.ose-immuno.com/wp-content/uploads/2026/05/OSE-PR_EN_260528_IRIS-Financing-vdef.pdf","note":"Flexible bridge equity financing (warrants) with IRIS Capital Investment: up to 4 million new shares, gross proceeds up to about EUR 19.3 million over 24 months at the then share price"}]},"route":"/companies/ose-immunotherapeutics/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/"}],"trial":[{"id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/"},{"id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","route":"/trials/nct06472245/"}]}}